The Effect of Coconut Oil on Alopecia

The Effect of Coconut Oil on Alopecia in Women Receiving Doxorubucin-Cycylophosphamide Treatment for Breast Cancer

İn this study will be conducted to evaluate the effect of coconut oil on alopecia in 86 female breast cancer patients treated at Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital between 01.02.2025-31.12.2025.

Study Overview

• Status: Recruiting
• Conditions: Breast Cancer
• Intervention / Treatment: Other: Coconut Oil

Detailed Description

Cancer is a disease in which the cells in our body multiply uncontrollably and develop by metastasizing, and the symptoms, course and consequences of the disease can show complex qualities in each patient. Cancer treatments have benefits and harms. One of these side effects is alopecia.

Alopecia due to cancer treatments is a condition of hair loss, partial or complete, usually temporary but rarely permanent.

In chemotherapy-induced alopecia, the hair follicle is damaged due to the pause in the anagen phase and causes the hair to break off spontaneously during activities such as washing and brushing the hair.

Various scales are used in the evaluation of alopecia due to cancer treatments, such as the National Cancer Institute Common Terminology Criteria for Side Effects and the Dean Alopecia Scale.

Some applications are made to prevent and treat alopecia. These include strategies and pharmacological applications to physically reduce the amount of medication given to the hair follicle.

Coconut oil helps regrow damaged hair. It provides essential proteins necessary for hair and softens the scalp and hair.

In the literature, it has been observed that studies showing the effects of coconut oil for the prevention and treatment of alopecia are insufficient. This study will be conducted on 86 breast cancer patients to determine the effect of coconut oil on the development of alopecia.

• Study Type: Interventional
• Enrollment (Estimated): 86
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: İsmail Dakdevir, Nurse; Phone Number: +905533228416; Email: dakdevirismail@gmail.com

Study Locations

• Turkey
  • Yenimahalle
    • Ankara, Yenimahalle, Turkey, 06170
      • Recruiting
      • Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• • To have been diagnosed with breast cancer.

  • The chemotherapy treatment plan should be planned as the Doxorubicin-Cyclophosphamide protocol.
  • Volunteer to participate in the study.
  • Be 18 years of age or older.
  • Being a woman.

Exclusion Criteria:

• • Having any health problem or disability that prevents communication (vision-hearing problems, neurological, psychiatric diseases).

  • Planning other treatments other than the Doxorubicin-Cyclophosphamide protocol for the treatment of breast cancer.
  • Not volunteering to participate in the study.
  • Having previously experienced any disease/skin problem that causes hair loss.
  • Having received chemotherapy before.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Experimental group; At the beginning of the study,patients will be asked to fill out an individual information form containing demographic information and disease process before the first chemotherapy application.The coconut oil application protocol will be explained to the patients in the experimental group and 10 milliliters of coconut oil will be applied to the hair follicles once a week. Alopecia assessment will be done every week.	Other: Coconut Oil; The coconut oil application protocol will be explained to the patients in the experimental group and 10 milliliters of coconut oil will be applied to the hair follicles once a week. Alopecia assessment will be done every week.
No Intervention: Control Group; At the beginning of the study,patients will be asked to fill out an individual information form containing demographic information and disease process before the first chemotherapy application. Patients in the control group will be asked not to apply anything to their hair. In each subsequent week, the presence of hair loss of the patients will be evaluated with the alopecia evaluation scale.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
National Cancer Instute (NCI) Common Terminology Criteria for Adverse Events (CTCAE); Alopecia	Grade 1; Hair loss of <50% of normal for that individual that is not obvious from a distance but only on close inspection; a different hair style may be required to cover the hair loss but it does not require a wig or hair piece to camouflage Grade 2; Hair loss of >=50% normal for that individual that is readily apparent to others; a wig or hair piece is necessary if the patient desires to completely camouflage the hair loss; associated with psychosocial impact	1-12 WEEK

Collaborators and Investigators

• Sponsor: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
• Collaborators: Çankırı Karatekin University

Study record dates

Study Major Dates

• Study Start (Actual): February 3, 2025
• Primary Completion (Estimated): December 31, 2025
• Study Completion (Estimated): January 31, 2026

Study Registration Dates

• First Submitted: February 5, 2025
• First Submitted That Met QC Criteria: February 5, 2025
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: February 8, 2025
• Last Verified: February 1, 2025

More Information

Terms related to this study

• Keywords: Breast Cancer; Alopecia; Coconut Oil
• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Pathological Conditions, Anatomical; Skin Diseases; Breast Diseases; Hypotrichosis; Hair Diseases; Breast Neoplasms; Alopecia Areata; Alopecia
• Other Study ID Numbers: Ankara Onkoloji EAH

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No